LAV
Venture capitalActively deployingHong Kong · Seed–Series C · 3 people tracked
Also known as LAV ADVANCED MANAGEMENT COMPANY LIMITED · LAV Biosciences · LAV Brassicanapus · LAV GLOBAL MANAGEMENT COMPANY LIMITED · LAV INVESTMENT ADVISER LIMITED · LAV MANAGEMENT COMPANY, LIMITED
Find your way into LAV
7 people in our graph share verified history with the LAV team — schools, employers, funds. One of them is your warm intro.
Investment thesis
LAV is a biomedical-focused venture capital firm that positions itself as a long-term partner to exceptional entrepreneurs building companies with breakthrough health products. The firm emphasizes domain expertise, global resources, and patient long-term capital. Its investment scope covers biopharmaceuticals, human therapeutics, medical devices, and diagnostics. LAV describes itself as a long-term thinker that bets on people, products, and quality science, aiming to be a trusted partner offering smart capital to help build great companies.
Source: firm website, verified Sep 15, 2026.
Team · 3 people
from public directoriesWhat they invest in
from 50 of 87 portfolio companiesBiotech ×46Healthtech ×32Medical Devices ×25Digital Health ×11Deep Tech ×10AI & Machine Learning ×7Hardware ×5Longevity ×2
HQs:China×22United States×22Germany×1
Who they back
founder profiles across 22 portfolio companiesFounding team size:solo founder×142 founders×63 founders×14+ founders×1
Where their founders studiedfrom 14 founders with education data
Fudan University ×3
What their founders studiedfrom 14 founders with field-of-study data
Life Sciences ×7Chemistry ×3Business & Management ×2Computer Science ×2Medicine ×2Physics ×2
Where their founders worked beforefrom 15 founders with career history
Insilico Medicine ×2
Investments · 87 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 12023 · 12022 · 12021 · 32020 · 22019 · 12018 · 12017 · 113 dated
Agilent manufactures laboratory instruments, software, reagents, and consumables for pharmaceutical, diagnostics, clinical research, and applied markets including chemicals, food, and environmental sectors.
William Redington HewlettPadraig McDonnell(President and Chief Executive Officer)
Co-investorsCalifornia Technology VenturesCatalyst Health VenturesExcel Venture Management
Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.
Elizabeth Buck(Chief Scientific Officer)Brent Hatzis-Schoch(Chief Operating Officer and General Counsel)Sergey Yurasov(Chief Medical Officer)Melanie Morrison(Chief Development Officer)
Co-investorsLilly Asia VenturesNew Enterprise Associates (NEA)Nextech InvestNSG VenturesRA CapitalVersant Ventures+3 more
Legend Biotech is a biotechnology company.
BiotechSomerset, US
Yuan Xu, Ph.D.(Executive Officer, Director)Ying Huang, Ph.D.(Executive Officer)Fangliang Zhang, Ph.D.(Director)Ye Wang, M.S.(Director)
Co-investorsLilly Asia Ventures
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in
Co-investorsBay City CapitalCanaan PartnersLilly Asia VenturesPfizer Venture InvestmentsQuan CapitalSofinnova Ventures+4 more
Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.
BiotechHealthtech
Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)
Co-investorsAtlas VentureJanus Henderson InvestorsvenBio Partners
Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases.
BiotechHealthtechMedical DevicesSuzhou, CN
Co-investorsLilly Asia VenturesOrbiMedExome Asset ManagementJanus Henderson InvestorsPivotal Life SciencesRA Capital+2 more
Airdoc, founded in 2015, develops AI medical products built on its Wanyu AI medical large model, including retinal screening (Retina-AI), myopia prevention (PBM-AI), and stress-resistance monitoring (Neuro-AI).
AI & Machine LearningDigital HealthHardwareHealthtechMedical Devices
Co-investorsLilly Asia Ventures
An innovative biopharmaceutical company focused on developing therapies for chronic kidney disease across multiple clinical stages, with a pipeline of eight products covering conditions such as hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.
BiotechDigital HealthHealthtechMedical DevicesShanghai, CN
Co-investorsLilly Asia VenturesQuan Capital3E Bioventures Capital3H Health InvestmentSherpa Healthcare PartnersYuanBio Venture Capital
A pharmaceutical and life sciences company developing drug pipelines and conducting research and innovation activities.
BiotechHealthtechMedical DevicesShanghai, CN
Du JinhaoGuo Jianhui(Co-founder)
Co-investorsYuanBio Venture CapitalLilly Asia Ventures
Ansun develops novel therapeutic treatments targeting viral diseases, particularly respiratory infections, through its proprietary sialic acid biology platform.
BiotechDigital HealthMedical DevicesSan Diego, US
RONALD MOSS(Executive Officer)inMARK ATTEBURY(Executive Officer)inMIKAEL HAVLUCIYAN(Executive Officer)
BoardMICHAEL CHANG(Director)Nancy Chang(Chairperson of the Board)Allen Chao(Director)
Co-investorsLilly Asia Ventures
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)inBrent Rice(Chief Commercial Officer)in
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHongShan Capital GroupLilly Asia VenturesOrbiMed+2 more
.png)
BiotechHealthtechMedical DevicesWaltham, US
David F. Muller(Executive Officer, Director)inBrian J. Roberts(Executive Officer)inRhonda J. Bracey(Executive Officer)in
BoardJason Hong(Director)Jeff Dykan(Director)inAnthony Natale(Director)in
Co-investorsAPERTURE Venture PartnersLilly Asia VenturesSCP Vitalife PartnersThird Point VenturesHealthQuest CapitalOrbiMed
Betta Pharmaceuticals is a Chinese biopharmaceutical company focused on innovative oncology drug research and development, with a portfolio of marketed anti-tumor drugs primarily targeting non-small cell lung cancer.
BiotechHealthtechMedical DevicesHangzhou, CN
Co-investorsLilly Asia Ventures
Burning Rock Biotech is a diagnostics company applying next-generation sequencing technology to precision oncology, offering NGS-based assays for tissue and blood samples alongside a proprietary database for clinical trial studies and research.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsLilly Asia Ventures
A company that manufactures vaccines, specifically an absorbed tetanus vaccine using an animal component-free fermentation process.
BiotechHealthtechMedical DevicesTianjin, CN
Co-investorsLilly Asia Ventures
Xian-ping LU(Founder)in
Co-investorsLilly Asia VenturesLYZZ CapitalVertex Ventures China
Connect Biopharm develops next-generation therapeutics for inflammatory diseases.
Biotech
Co-investorsLilly Asia VenturesQiming Venture Partners
CorrectSequence Therapeutics develops base-editing gene therapies using its proprietary transformer Base Editor (tBE) platform to treat genetic diseases, rare diseases, and common conditions including inherited disorders, metabolic diseases, cardiovascular diseases, and cancers.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesShanghai, CN
陈佳(Founding Professor / Chief Scientific Advisor)牟晓盾(Chief Executive Officer)
Co-investorsLilly Asia Ventures
Crown Bioscience is a contract research organization based in California providing discovery, preclinical, and translational platforms and services for oncology and immuno-oncology drug development.
BiotechHealthtechMedical DevicesCalifornia, US
Co-investorsAcorn Pacific VenturesGRC SinogreenLilly Asia VenturesQiming Venture Partners
Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.
BiotechDigital Health
Co-investorsLilly Asia VenturesMPM BioImpactSchooner CapitalTaiho Ventures, LLC
EdiGene is a biotechnology company developing genome-editing-based therapies, including allogeneic cell therapies and in vivo RNA base editing platforms, alongside a high-throughput genome editing screening platform.
BiotechDeep TechHealthtech
Co-investorsLilly Asia VenturesWI Harper Group3H Health InvestmentAlwin CapitalBioTrack CapitalIDG Capital+2 more
Skyline Therapeutics develops gene therapy vector technology and supports clinical development for therapeutic applications using genetic science approaches.
BiotechDeep TechHealthtech
Co-investorsF-Prime CapitalLilly Asia Ventures
Geneseeq develops next-generation sequencing (NGS) based genetic tests and in-vitro diagnostic products for cancer patients, using gene profiling to guide targeted drug selection, indicate drug resistance mechanisms, and monitor post-surgical recurrence.
AI & Machine LearningBiotechDigital HealthNanjing, CN
Co-investorsLilly Asia Ventures
Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.
BiotechDeep TechHealthtechSan Carlos, US
Wayne(CEO)Rachel(VP of Operations)
Co-investorsBay City CapitalGV (Google Ventures)Lilly Asia Ventures
Huamai Taike develops and manufactures medical devices including vascular stents, catheters, guidewires, and hemostatic devices for interventional vascular and neurovascular procedures.
HardwareHealthtechMedical DevicesBeijing, CN
Co-investorsLilly Asia Ventures
Inhibrx develops protein therapeutics, using target biology and protein engineering to create therapeutic candidates in clinical trials for conditions including sarcoma and head and neck cancer.
BiotechLa Jolla, US
Mark Lappe(Executive Officer, Director)inBrendan Eckelman(Director)inDoug Forsyth(Director)Jon Faiz Kayyem(Director)Margery Fischbein(Director)
BoardJudith Li(Director)
Co-investorsLilly Asia VenturesRA CapitalOxford Finance LLC
Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development.
AI & Machine LearningBiotechDigital HealthHealthtechHong Kong
Alex Zavoronkov(Director)Alex Zhavoronkov(Founder & CEO)inAlex Aliper(President)inFeng Ren(Chief Scientific Officer, Executive Director & Co-CEO)in
BoardNisa Leung(Director)Lennart Lee(Director)
Co-investorsLilly Asia VenturesOrbiMedQiming Venture PartnersWarburg PincusBaidu VenturesEight Roads Ventures+9 more
InventisBio is a China-based drug discovery company developing patent-protected small-molecule targeted therapies for oncology and metabolic diseases.
BiotechHealthtechShanghai, CN
Xing Dai(Founder)inYaolin Wang(Chairman & General Manager (Co-founder))in
Co-investorsLilly Asia VenturesOrbiMedQiming Venture Partners
A clinical-stage biotech company developing novel targeted cancer therapies and immunomodulatory drugs with a global equity strategy.
BiotechHealthtechMedical DevicesShenzhen, CN
Co-investorsLilly Asia Ventures
Jacobio is a biopharmaceutical company developing novel oncology therapeutics, focusing on next-generation antibody-conjugated drugs including ATDCs, ISACs, and AOCs to treat cancer patients.
BiotechDeep TechHealthtechMedical DevicesBeijing, CN
Wang Yinxiang(Chairman and Co-Chief Executive Officer)Wang Yi(Co-Chief Executive Officer, Chief Medical Officer)
Co-investorsLilly Asia VenturesQiming Venture Partners
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)JAMES GILBERT(Director)
BoardALAN L. CRANE(Director)
Co-investorsAlpha Wave GlobalARCH Venture PartnersFlagship PioneeringLG Technology VenturesLilly Asia VenturesBaillie Gifford+1 more
Lupeng Pharmaceutical develops next-generation small-molecule targeted drugs for malignant tumors and autoimmune diseases, focusing on hematologic cancer targets such as BTK, Bcl-2, and Bcl-xL, with multi-center clinical development and commercialization in international and Chinese markets.
BiotechHealthtech
周正清(首席财务官 (CFO))Stephen Anthony(首席医学官 (Chief Medical Officer))
Co-investorsLilly Asia VenturesOrbiMed
Lynk Pharma develops pharmaceutical products for rheumatoid arthritis and ankylosing spondylitis, with selective licensing arrangements for regional commercialization.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesHangzhou, CN
Zhao-Kui (ZK) Wan(Founder, Chairman of Board & CEO)Michael Vazquez(Co-founder & Executive Vice President)inJun Wang(Co-founder & CSO)inYan Chen(Co-founder & COO)in
Co-investorsDecheng CapitalLilly Asia Ventures
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsage1EcoR1 CapitalLilly Asia VenturesNew Enterprise Associates (NEA)Vivo CapitalARCH Venture Partners+2 more
MicroTech Medical provides medical information services in China, with operational headquarters in Hangzhou and a principal place of business in Hong Kong.
Digital HealthHardwareMedical DevicesHangzhou, CN
Co-investorsLilly Asia VenturesLYZZ CapitalQiming Venture Partners
Milliin (迈淩) develops hemodialysis equipment and related products, including dialysis machines, dialysis water treatment systems, centralized concentrate supply systems, and dialysis dry powder.
HardwareHealthtechMedical Devices
Co-investorsLilly Asia Ventures
NiKang Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cancer, using structure-based drug design against targets such as HIF2α, CDK2, KRAS, and SHP2.
BiotechHealthtechWilmington, CN
Yan Lou(Founder)inZhenhai Gao(President, CEO, and Secretary)Hong (Kelsey) Chen(Chief Financial Officer)
BoardGary Yeung(Director)Ting Jia(Director)Roderick Wong(Director)
Co-investorsEcoR1 CapitalLilly Asia VenturesRA CapitalSamsara BioCapitalThe Innovation SpaceLogos
BiotechCampbell, US
Amr Salahieh(Executive Officer, Director)Casey Gordon(Director)Mariam Maghribi(Executive Officer)
Co-investorsLilly Asia VenturesThe Capital Partnership
Perfuse Therapeutics develops novel ocular therapies for retinal and glaucoma diseases through drug delivery and formulation platforms.
BiotechHealthtechMedical DevicesSan Francisco, US
Sevgi Gurkan, MD(Founder, Chief Executive Officer, and Member of the Board of Directors)in
BoardChristy Shaffer(Director)Chau Khuong(Director)inSevgi Gurkan(Executive Officer, Director, Promoter)in
Co-investorsOrbiMedAccess BiotechnologyCatalio Capital Management, LPHatteras Venture PartnersLilly Asia VenturesHatteras
Pinnacle Medicines develops oral peptide-based therapies designed to deliver antibody-like efficacy in pill form for patients with chronic diseases.
BiotechDigital HealthDoylestown, US
Chengzao Sun(Founder)inSandeep Somani(Founder)in
Co-investorsForesite CapitalQuan CapitalRA CapitalOrbiMed
Hangzhou-based gene-editing biotech developing immune-privileged cell therapies and xenogeneic organs for transplant and cancer.
Co-investorsAlta PartnersARCH Venture PartnersSequoia Capital
Readcoor developed an in situ spatial transcriptomics platform using padlock probe rolling circle amplification chemistry to detect and map RNA transcripts across tissue sections, now offered as the Xenium In Situ platform.
BiotechDeep TechHardwareHealthtechCambridge, US
Evan Daugharthy(Cofounder)Richard Terry(Executive Officer, Director)
BoardYuh-Geng Tsay(Director)Victor Tong(Director)Thomas Grogan(Director)
Co-investorsLilly Asia VenturesLilly VenturesVivo Capital
Regor is a drug discovery company that uses a computational platform (rCARD) to identify and optimize preclinical small-molecule candidates in metabolism, oncology, and immunology, which it licenses to pharmaceutical companies for clinical development.
AI & Machine LearningBiotechDeep TechShanghai, CN
Xiayang Qiu(Founder)in
Co-investorsLilly Asia VenturesVertex VenturesVertex Ventures China
RemeGen is a biopharmaceutical company that develops and commercializes novel antibody and fusion protein therapeutics, including telitacicept (a BLyS/APRIL dual-target fusion protein) and disitamab vedotin, for conditions such as autoimmune diseases and cancers.
BiotechHealthtechYantai, CN
王威东(Co-founder)房健民(Co-founder)
Co-investorsLilly Asia Ventures
Rona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH.
BiotechLongevityShanghai, CN
Jinyu Huang(Chief Executive Officer, Founder)Stella Shi(Founder & Chief Executive Officer, Chair of the Board)in
Co-investorsLilly Asia Ventures
SciNeuro develops targeted therapeutics for neurodegenerative and age-related brain diseases by integrating patient genetics, health history, and advanced diagnostic tools.
BiotechDeep TechDigital HealthLongevityMedical DevicesRockville, US
Min Li(CEO & Director)inSam Agus(CSO/CMO)Paul Stead(CBO)in
Co-investorsARCH Venture Partners
Singlera is a biotech company specializing in in vitro diagnostic reagents and instruments.
BiotechDeep TechDigital HealthHealthtechMedical DevicesShanghai, CN
Zhang Jiangli(Co-founder, Chairman & CEO)inZhang Hun(Co-founder)
Co-investorsDetong CapitalLilly Asia Ventures
Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples.
BiotechMedical DevicesCologne, DE
Co-investorsARCH Venture PartnersLilly Asia VenturesLake Bleu CapitalMSA CapitalSBCVCSherpa Healthcare Partners
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Executive Officer, Director, Promoter)in
BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)
Co-investors8VCARCH Venture PartnersFrazier Life SciencesJDRF T1D FundLifeforce CapitalLilly Asia Ventures+1 more
A biotech company focused on researching and commercializing treatments for genetic rare diseases in China, aiming to address unmet medical needs and improve patient access to advanced therapeutics.
BiotechHealthtechMedical DevicesYangzhou, CN
严知愚(Co-founder, Chairman & CEO)王晓晖(Co-founder, Chief Business & Operations Officer)
Co-investorsLilly Asia Ventures
Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.
BiotechHealthtechBrisbane, US
Stephen Brady(Director)Matthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)inThomas W. Dubensky, Jr.(Executive Officer, Director)Thomas Woiwode(Director)Geoffrey Nichol(Director)
Co-investorsF-Prime CapitalLilly Asia VenturesNew Enterprise Associates (NEA)Quan CapitalRoche Venture Fund
Terns Pharmaceuticals is a biopharmaceutical company developing therapies, including its TERN-701 program.
BiotechHealthtechFoster City, US
Mark Vignola, Ph.D.(Executive Officer)Bryan Yoon(Executive Officer)inSenthil Sundaram(Director, Executive Officer)inWeidong Zhong, Ph.D.(Executive Officer, Director)Jill Quigley(Director)inDavid Fellows(Director)
Co-investorsDecheng CapitalLilly Asia VenturesVivo Capital
BiotechPhiladelphia, US
Anne Chew(Director and President)
BoardKevin Mahoney(Director)
Co-investorsAndreessen HorowitzKleiner PerkinsLilly Asia VenturesMilitia Hill VenturesGilead Sciences
Innovative biopharma company focused on cancer and immune disease therapies (SHSE: 688192).
Co-investorsHongShan Capital GroupLilly Asia Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ADARx Pharmaceuticals, Inc.Avenzo Therapeutics, Inc.3SbioAbbiskoAceabioArmobioAusunpharmCaldera Therapeutics, Inc.CarsgenChinesepeptideElpiscienceFountain MedHD BiosciencesIMPACT TherapeuticsInnovent BiologicsJustbiochinaMabspacebioMediTrust HealthNewhorizonbioNovastPinsmedicalProfound BioPulnovo MedicalSinqiSzyhloTargetingoneTurning Point TherapeuticsVirtuedxXihuasci凯因科技博瑞医药圣湘生物
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 6
5 IPOs · 1 acquisitions · showing 5AgilentNYSE: ABlack Diamond Therapeutics, IncNASDAQ: BDTXLegend BiotechNASDAQ: LEGNNextCureNASDAQ: NXTCAvedroacq. by Glaukos
Portfolio news
latest coverage across their companiesLegend Biotech · theaiinsider.tech · Sep 17, 2026
Agilent · investing.com · Sep 16, 2026
Black Diamond Therapeutics, Inc · finance.yahoo.com · Sep 2, 2026
Inhibrx · ng.investing.com · Aug 21, 2026
Terns Pharmaceuticals · tradingkey.com · Aug 20, 2026
Arrivent · tickerreport.com · Aug 17, 2026
Alebund · fiercebiotech.com · Aug 12, 2026
Fund performance · per public LP disclosures · 2
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| LAV Opportunities FundLPs: The Regents of the University of California | 2020 | — | 3.4% | 1.10x | 0.17x |
| LAV VILPs: The Regents of the University of California | 2020 | — | 9.8% | 1.26x | 0.35x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- How many investments has LAV made?
- LAV has 87 tracked investments, 6 of which have exited, including 3 dated in the last 24 months.
- What stage does LAV invest at?
- LAV invests at the Seed, Series A, Series B, Series C stages.
- What is LAV's typical check size?
- LAV typically writes checks of $5M – $15M.
- What sectors does LAV focus on?
- LAV focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is LAV located?
- LAV is headquartered in Hong Kong, HK.
- Who does LAV co-invest with?
- LAV most often shares deals with Lilly Asia Ventures, Qiming Venture Partners, OrbiMed, among 66 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.